1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Novacyt
  6. Summary
    ALNOV   FR0010397232

NOVACYT

(ALNOV)
  Report
Real-time Euronext Paris  -  11:35 2022-08-08 am EDT
1.417 EUR   +1.21%
08/04Novacyt Launches First Fully Lyophilized Direct-to-PCR Assays; Shares Up 5%
MT
08/04Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-PCR Assays
CI
07/28Novacyt Creates Research-use-only Adenovirus F41 Test Kit Amid Rising Hepatitis Cases
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
08/02/2022 08/03/2022 08/04/2022 08/05/2022 08/08/2022 Date
1.34(c) 1.355(c) 1.388(c) 1.4(c) 1.417(c) Last
131 917 658 626 452 552 120 488 166 807 Volume
-2.69% +1.12% +2.44% +0.86% +1.21% Change
More quotes
Estimated financial data (e)
Sales 2020 277 M - -
Net income 2020 132 M - -
Net cash position 2020 89,4 M - -
P/E ratio 2020 5,05x
Yield 2020 -
Sales 2021 95,8 M - -
Net income 2021 -9,73 M - -
Net cash position 2021 99,9 M - -
P/E ratio 2021 -31,3x
Yield 2021 -
Capitalization 100 M 102 M -
EV / Sales 2020 2,17x
EV / Sales 2021 2,19x
Nbr of Employees 276
Free-Float 94,8%
More Financials
Company
Novacyt develops, produces, and sells in vitro and molecular diagnostic products for the microbiology, haematology and serology markets. The activity is organized around two sectors: - development of solutions and diagnostic services. The group is also developing a manufacturing activity for reagents and kits for bacterial and blood tests; - manufacture and sale of molecular screening kits (Primerdesign): for... 
More about the company
All news about NOVACYT
08/04Novacyt Launches First Fully Lyophilized Direct-to-PCR Assays; Shares Up 5%
MT
08/04Novacyt Announces the Launch of the First Fully Lyophilised (Freeze-Dried), Direct-To-P..
CI
07/28Novacyt Creates Research-use-only Adenovirus F41 Test Kit Amid Rising Hepatitis Cases
MT
07/28Novacyt S.A. Launches Research-Use-Only Adenovirus F41 Assay
CI
07/21NOVACYT : Results of Annual General Meeting
PU
07/21NOVACYT : AGM Investor Presentation
PU
07/15Novacyt - Approval of exsig COVID-19 Direct test in the UK under CTDA legislation
AQ
07/15UK Watchdog OKs Novacyt's exsig COVID-19 Direct Test
MT
07/15Novacyt S.A. Announces Approval of exsig COVID-19 Direct test in the UK
CI
07/07NOVACYT : Half-year results
CO
06/30NOVACYT : Monthly statement on outstanding equity shares and voting rights
CO
06/28France's Novacyt Rolls Out Monkeypox Assay
MT
06/28Novacyt Announces the Launch of Its Research-Use-Only Polymerase Chain Reaction Monkeyp..
CI
06/21NOVACYT : Mixed general shareholder meeting
CO
06/19NOVACYT : Convening notice for 21st June 2022
PU
More news
News in other languages on NOVACYT
08/04CAC40 : franchit les 6.500 porté par les valeurs bancaires
08/04Novacyt lance les premiers tests Direct-to-PCR entièrement lyophilisés ; les actions so..
08/04CAC40 : s'approche des 6500, porté par les valeurs bancaires
08/04NOVACYT : lancement de nouveaux tests PCR lyophilisés
08/04BOLSA DE MADRID : La tecnología está cansada de ir cuesta abajo
More news
Chart NOVACYT
Duration : Period :
Novacyt Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVACYT
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Managers and Directors
David Allmond Chief Executive Officer & Director
James Martin Mccarthy Chief Financial Officer & Director
James Christopher Wakefield Chairman
Paul Oladimeji Group Head-Research & Development
Bryan Close Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVACYT-67.65%100
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
MODERNA, INC.-26.44%73 092
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499